🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On Tuesday March 4, we will present our 4Q and full year 2024 financial results and provide a business update. Click below to register and watch the webcast. $WVE

Every day we strive to serve as a trusted partner and advocate to the #RareDisease community, determined to put patients and their families’ interests first. In celebration of #RareDiseaseDay we reflect on why we care about rare and what motivates us to unlock the full potential

Tomorrow, March 4, we will present our 4Q and full year 2024 financial results and provide a business update. Click below to register and watch the webcast. $WVE

Today we announced our 4Q & full year 2024 results and provided a business update, including the latest on our clinical trials for WVE-007 in #obesity and WVE-006 in #AATD, as well as expected milestones across our pipeline for 2025. $WVE

What a great week at #CHDI! Our team had productive conversations with #HuntingtonsDisease researchers and advocates, and presented on our SELECT-HD results and how we are using biomarkers like caudate atrophy to rapidly advance WVE-003 for HD. View our CHDI posters here:

We’re proud to have three Wave team members presenting at #OPTBoston this week! Join us Tuesday and Wednesday to learn more about our best-in-class oligonucleotide chemistry and how we’re opening up new hepatic and extrahepatic therapeutic applications using #RNAediting.

Our team helped Alpha-1 Foundation celebrate their 30th anniversary at the annual Celtic Connection this past weekend! It was an inspiring and beautiful night dedicated to raising awareness and showing support for #Alpha1! #AATD #Alpha1Community

As we strive to develop impactful therapies for individuals facing life-changing conditions such as #HuntingtonDisease, we remain dedicated to consistently engaging with and learning from the community. Jamie joined us at Wave this week to share her #HD journey, including her

Thank you HDYO for a wonderful weekend in #Prague and the chance to connect with young people in the #HuntingtonsDisease community. We know that every #HD story is unique and we’re grateful to hear the diverse perspectives of youth from around the world. Having worked in HD

This Saturday at the #CSHLNat meeting, Wave's Jack Godfrey will present on expanding therapeutic #RNAediting outside the liver, including to the lung and CNS. Learn more about Cold Spring Harbor Laboratory here: meetings.cshl.edu/meetings.aspx?…

This morning we shared positive data from the Phase 2 FORWARD-53 trial of WVE-N531 in #Duchenne where we observed significant functional benefits and reversal of muscle damage after 48 weeks of dosing. Click below to more about these data. $WVE

We are pleased to announce positive data from the Phase 2 FORWARD-53 trial of WVE-N531, as well as our plans to file an NDA in 2026 for accelerated approval. Join us this morning at 8:30 AM ET for an investor conference call where we’ll discuss the results. $WVE

On Thursday May 8, we will present our 1Q earnings update. Click below to register and listen to the webcast. $WVE

Tomorrow, we will present our 1Q earnings update. Webcast registration here: edge.media-server.com/mmc/p/9zuegoop/ $WVE

Today we announced our 1Q 2025 earnings update, including progress advancing our clinical trials for WVE-007 in #obesity and WVE-006 in #AATD and highlighting our differentiated programs in #Duchenne and #HuntingtonsDisease. $WVE

Today we announced the appointment of Chris Wright, MD, PhD, as our Chief Medical Officer. Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide development of Wave’s robust #RNA medicines pipeline. Click below for more. $WVE

Our President and CEO, Paul Bolno, will be participating in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4. Save the date and register for the webcast below. #JefferiesHealthcare $WVE

#ICYMI: This week we announced the appointment of Chris Wright, MD, PhD, as our Chief Medical Officer. Learn more about Dr. Wright and his role at Wave here: ir.wavelifesciences.com/news-releases/… $WVE

Attending the Alpha-1 Foundation National Conference? Join us Saturday at 11:55 a.m. to learn about our #RNAediting platform and our RestorAATion-2 trial of WVE-006 for people with #AATD. #A1FNC25 #Alpha1

Wave’s success is built on our team’s drive, passion, and collaboration. Anthony Murabito, our VP of IT and Chief of Data Security, talks to The Swan Group's Biotech Bytes podcast about how we think about talent management, the potential of AI, and more.